SCHEMBL294583

SCHEMBL294583

CNC1(c2ccccc2)CCCC1

nearest known ligand 0.96

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 7/20 0.63
OPRL1 P41146 7/20 0.63
OPRK1 P41145 1/20 0.63
SLC6A4 P31645 1/20 0.50
GRIN2D O15399 1/20 0.46
GRIN3B O60391 1/20 0.46
GRIA1 P42261 1/20 0.46
GRIA2 P42262 1/20 0.46
GRIA3 P42263 1/20 0.46
GRIA4 P48058 1/20 0.46
GRIN1 Q05586 1/20 0.46
GRIN2A Q12879 1/20 0.46
GRIN2B Q13224 1/20 0.46
GRIN2C Q14957 1/20 0.46
GRIN3A Q8TCU5 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL294762 0.98 OPRM1 (0.61) OPRM1OPRL1OPRK1SLC6A4GRIN2D
Hydrochloric Acid SCHEMBL28148666 0.96 OPRM1 (0.59) OPRM1OPRL1OPRK1SLC6A4GRIN2D
SCHEMBL294971 0.95 OPRM1 (0.63) OPRM1OPRL1OPRK1SLC6A4GRIN2D
SCHEMBL1822928 0.91 OPRM1 (0.74) OPRM1OPRL1OPRK1SLC6A4
Hydrochloric Acid SCHEMBL28226628 0.88 OPRM1 (0.71) OPRM1OPRL1OPRK1SLC6A4
SCHEMBL7552235 0.81 OPRM1 (0.58) OPRM1OPRL1OPRK1SLC6A4
SCHEMBL5671696 0.81 OPRM1 (0.58) OPRM1OPRL1OPRK1SLC6A4
SCHEMBL5036687 0.81 OPRM1 (0.58) OPRM1OPRL1OPRK1
SCHEMBL3707243 0.81 OPRM1 (0.49) OPRM1OPRL1OPRK1
SCHEMBL8353019 0.80 OPRM1 (0.43) OPRM1OPRL1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116377727-A Laser stealth coating for fabric and application method thereof 西京学院 2023-07-04 CN claimed
CN-116377727-A Laser stealth coating for fabric and application method thereof 西京学院 2023-07-04 CN disclosed
CN-114450277-A Substituted pyrimidines for the treatment and prevention of hepatitis B virus infection 豪夫迈·罗氏有限公司 2022-05-06 CN disclosed
EP-2945950-B1 ISOMANNIDE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE SANOFI SA (FR) 2017-03-01 EP disclosed
US-8344004-B2 Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals SANOFI (FR) 2013-01-01 US disclosed
EP-2240474-B1 CYCLIC PYRIDYL-N-(1,3,4)-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2012-03-14 EP disclosed
US-20110224263-A1 Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2011-09-15 US disclosed
EP-2261218-A2 Process for preparing phenyl-, pyridinyl- or pyrimidinyl-substituted imidazoles Eisai R&D Management Co., Ltd. (JP) 2010-12-15 EP disclosed
CN-101910162-A Cyclic pyridyl-N- [1,3,4] -thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals SANOFI AVENTIS 2010-12-08 CN disclosed
EP-1937659-B1 CYCLIC N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI AVENTIS (FR) 2010-11-10 EP disclosed
WO-2007058960-A1 SULFAMOYL BENZAMIDES AS CANNABINOID RECEPTOR MODULATORS ADOLOR CORPORATION (US) 2007-05-24 WO disclosed
WO-2007039173-A1 CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 WO disclosed
EP-1757591-A1 CINNAMIDE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-02-28 EP disclosed
WO-2007020502-A2 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF PHARMACIA & UPJOHN COMPANY LLC (US) 2007-02-22 WO disclosed
WO-2006102308-A2 BETA-LACTAMYL VASOPRESSIN V1B ANTAGONISTS AZEVAN PHARMACEUTICALS, INC. (US) 2006-09-28 WO disclosed
EP-0625507-B1 Urea derivatives and their use as acat inhibitors NISSHIN FLOUR MILLING CO (JP) 1997-07-23 EP disclosed
US-5621010-A ANTIHYPERCHOLESTEROLEMIA AND ANTIATHEROSCLEROSIS NISSHIN FLOUR MILLING CO., LTD. (JP) 1997-04-15 US disclosed
EP-0703899-A1 ARYLACETAMIDES, PROCESS FOR THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND THEIR USE AS FUNGICIDES Hoechst Schering AgrEvo GmbH (DE) 1996-04-03 EP disclosed
WO-1994029267-A1 ARYLACETAMIDES, PROCESS FOR THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND THEIR USE AS FUNGICIDES HOECHST SCHERING AGREVO GMBH (DE) 1994-12-22 WO disclosed
EP-0625507-A2 Urea derivatives and their use as acat inhibitors NISSHIN FLOUR MILLING CO., LTD. (JP) 1994-11-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224263-A1 Cyclic pyridyl-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals PPARD, PPARG, PPARA OPRM1 3188/4885OPRL1 2675/4885OPRK1 2292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.